85 results
Page 2 of 5
6-K
EX-99.3
2pf5zo5g mj5
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
n0w4slug82s
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-99.1
97lq bdpdpymb
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.1
mx4 juolcgak
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
EX-99.2
9gwjh qj2
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
kf37me5of kucu9p
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.1
luf36zriw nyecp9a
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.2
u4t8yu7vmxc5 q4
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
71wpn
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.3
ufifla2 tazxo05p3pex
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
cu3e51
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
pzvi3a0j
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
bgjg10awupfpjvre0zz
12 Oct 21
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
7:30am
6-K
EX-99.1
ouc7o iysq5ey
12 Oct 21
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
7:30am
6-K
EX-99.1
dx83 lajvvt3f7m14rpq
10 Aug 21
InflaRx Announces Positive Data from Second Interim Analysis
7:30am
6-K
EX-99.3
tln65yarn mkyux2do
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
nm32f gu83s
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
m71nve0q2b ya
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
dji1zd 5nok
12 May 21
Current report (foreign)
4:30pm